The Cardiac Prosthetic Devices Market, estimated at USD 8.96 Bn in 2025, is expected to exhibit a CAGR of 9.3% and reach USD 16.7 Bn by 2032.
The industry is witnessing significant growth driven by rising demand for advanced, reliable, and cost-effective medical devices across diagnostic, therapeutic, and monitoring applications. Rapid advancements in device design, digital health integration, and adoption of minimally invasive technologies are reshaping the competitive landscape. Furthermore, supportive regulatory frameworks, increasing healthcare investments, and the growing focus on patient-centric care are expected to create new growth avenues for market players.
The key market players are focused on gaining product approval from the U.S. FDA (Food and Drug Administration), which in turn is expected to drive the growth of the market over the forecast period. For instance, on March 30, 2025, Abbott, a medical device company, announced that the U.S. Food and Drug Administration (FDA) has approved the company's Epic Max stented tissue valve for the treatment of patients suffering from aortic regurgitation or stenosis. This device is the latest addition to Abbott's Epic surgical valve platform which has a decades-long history of safety and strong clinical outcomes, with an optimized design to further improve valve blood flow.
Global Cardiac Prosthetics Devices Market – Impact of Coronavirus (COVID-19) Pandemic
The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China) in the last months of 2025 as "coronavirus disease 2025" or COVID-19. This virus spread quickly and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.
COVID-19 affected the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries such as India, China, Brazil, and others faced problems with regard to the transportation of drugs from one place to another.
COVID-19 had a negative impact on the global cardiac prosthetics devices market, due to the lockdown imposed in the majority of the nations, several countries such as China, India, Germany, France, Saudi Arabia, UAE, Egypt, and others faced problems with regard to the transportation of products and raw materials from one place to another, which limited the market growth during the pandemic. Quarantine, traveling constraints, and social distancing measures led to a steep decline in business and consumer spending
Furthermore, healthcare providers were facing challenges in terms of additional manpower, equipment, consumables, and other resources, which were required to ensure safety in hospitals and provide treatment to patients with other diseases. This has impacted the overall healthcare market negatively.
Additionally, there were delays in hospitalization and surgical procedures as the number of patient visits decreased, which is expected to affect the global cardiac prosthetics devices market over the forecast period.
Global Cardiac Prosthetics Devices Market: Key Developments
Increasing product approval from the U.S., FDA (Food and Drug Administration), for the treatment of patients suffering from various cardiac diseases such as native or surgically-repaired right ventricular outflow tract (RVOT) and others is expected to fuel the market growth over the forecast period. For instance, in March 2025, the U.S. FDA (Food and Drug Administration), announced the approval of the Harmony Transcatheter Pulmonary Valve (TPV) System, which is a non-surgical heart valve to treat pediatric and adult patients with a native or surgically-repaired right ventricular outflow tract (RVOT), the part of the heart that carries blood out of the right ventricle to the lungs.